Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07404423

OPEN-IPF: Observational Prediction modEl for cliNical Outcomes in Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with marked inter-individual heterogeneity in trajectories and outcomes. Despite antifibrotic therapies, reliable risk stratification in routine practice remains suboptimal. OPEN-IPF is a multicentre retrospective observational cohort study designed to build a harmonised real-world dataset across Italian IPF referral centres to enable the development and external validation of machine-learning (ML) models predicting clinically relevant outcomes.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

OPEN-IPF addresses the current limitation of AI/ML research in IPF-namely, the lack of large multicentre real-world datasets with harmonised variables and robust external validation. The study will retrospectively include adult patients with IPF followed in routine practice in participating Italian referral centres from 1 January 2015 to 31 December 2025 (data lock). No study-specific procedures will be performed. De-identified/pseudonymised data will be collected using a common data model, including demographics, smoking history, comorbidities, pulmonary function (FVC, DLCO), oxygen requirement, 6-minute walk test (where available), antifibrotic treatment exposure, HRCT features routinely reported, basic laboratory parameters, and clinical outcomes. The primary modelling targets are disease progression, acute exacerbations of IPF (AE-IPF), and real-world response to antifibrotic treatment. Model development will be performed using multicentre data with explicit external validation across centres

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • Diagnosis of idiopathic pulmonary fibrosis established according to international guidelines and local multidisciplinary team (MDT) assessment
  • Availability of baseline clinical and functional data
  • Availability of follow-up data for at least 12 months, or until a clinically relevant event (e.g., death, lung transplantation)

Exclusion criteria

  • Interstitial lung disease other than IPF
  • Lung transplantation performed before the baseline (index) date
  • Absence of any follow-up information after baseline

Treatment and study plan

Primary outcomes

  1. Disease progression (guideline-based functional/composite criteria)

    Time frame: From baseline (index date) up to 12 months and up to end of available follow-up (maximum: 31 December 2025)

    Disease progression defined using guideline-based criteria derived from routinely collected clinical data (e.g., decline in lung function and/or composite progression definitions as per the shared operational document).

Secondary outcomes

  1. Acute exacerbation of IPF (AE-IPF)

    Time frame: From baseline to end of follow-up (maximum: 31 December 2025)

    Occurrence of AE-IPF during follow-up, adjudicated from routine clinical documentation using standardised operational definitions shared across centres.

  2. Real-world response to antifibrotic therapy

    Time frame: From treatment initiation (or baseline if already treated) up to 12 months and end of follow-up (maximum: 31 December 2025)

    Treatment response assessed in routine clinical practice using longitudinal clinical/functional data and treatment exposure information (type, start, discontinuation)

  3. Overall survival

    Time frame: From baseline to end of follow-up (maximum: 31 December 2025)

    Time from baseline to death from any cause.

  4. Transplant-free survival

    Time frame: From baseline to end of follow-up (maximum: 31 December 2025)

    Time from baseline to lung transplantation or death.

  5. Time to first progression or AE-IPF event

    Time frame: From baseline to end of follow-up (maximum: 31 December 2025)

    Time from baseline to first occurrence of disease progression or AE-IPF.

Study contacts

Contact information is provided by the study sponsor or research team.

Roberto Tonelli, MD, PhD

CONTACT

[email protected]

0039059425934

Stefania Cerri, MD, PhD

CONTACT

[email protected]

00390594225335

Sponsors and collaborators

Lead sponsor

University of Modena and Reggio Emilia

Other

Registry information

Official study title

Observational Prediction Model for Clinical Outcomes in Idiopathic Pulmonary Fibrosis: a Multicentre, ML-driven Study (OPEN-IPF)

Acronym: OPEN-IPF

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Feb 11, 2026
Registry last updated
Feb 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.